Skip to search formSkip to main contentSkip to account menu

SYN-004

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam… 
2017
2017
To evaluate an antibiotic inactivation strategy to protect the gut microbiome from antibiotic‐mediated damage. 
2017
2017
Abstract Background Clostridium difficile infections (CDI) are an “urgent threat,” but there are no approved drugs or vaccines to… 
2017
2017
P R I M A R Y E N D P O I N T C O N C L U S I O N S The use of intravenous β-lactam antibiotics, including cephalosporins, are an… 
2016
2016
BackgroundSYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous… 
2016
2016
SYN-004 is a first in class, recombinant β-lactamase that degrades β-lactam antibiotics and has been formulated to be… 
2016
2016
SYN-004 is a clinical stage oral β-lactamase therapy for use with intravenous (IV) β-lactam antibiotics to preserve the gut…